<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01752348</url>
  </required_header>
  <id_info>
    <org_study_id>11422796</org_study_id>
    <secondary_id>1-10-72-530-12</secondary_id>
    <nct_id>NCT01752348</nct_id>
  </id_info>
  <brief_title>Effects of Free Fatty Acids and 3-hydroxybutyrate on Protein, Glucose, Lipid Metabolism and Intracellular Signals.</brief_title>
  <official_title>Effects of Free Fatty Acids and 3-hydroxybutyrate on Protein, Glucose, Lipid Metabolism and Intracellular Signals; a Study on Muscle Wasting and Metabolism During Acute Inflammation and Potential Anabolic Mechanisms.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that the investigators can detect protein-sparing effects of
      administration of the ketone 3-hydroxybutyrate and free fatty acids during simulation of an
      acute inflammatory disease. The investigators use the infusion of endotoxin, US standard
      reference E.coli in healthy subjects as a model for inflammation / infection and to evaluate
      the effect on protein metabolism using different tracers and the investigators can measure
      the various intracellular signaling pathways of selected muscle and adipose tissue.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Protein metabolism</measure>
    <time_frame>6 hours intervention period</time_frame>
    <description>Measurements of protein oxidation during intervention using radioactive tracer techniques.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activated intracellular signalling pathways</measure>
    <time_frame>study day</time_frame>
    <description>Measurements on biopsies from muscle and fatty tissue taken on day of study</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Other systemic metabolic effects</measure>
    <time_frame>6 hours of intervention</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Systemic Inflammatory Response Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo (isotonic saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Endotoxin + isotonic saline. Reference for model of acute inflammatory illness</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acipimox + Placebo (isotonic saline)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endotoxin + Acipimox + Placebo (isotonic saline). Intervention: blockage of endogenous lipolysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acipimox + free fatty acids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endotoxin + Acipimox + free fatty acids. Intervention: free fatty acids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acipimox + 3-hydroxybutyrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endotoxin + Acipimox + 3-hydroxybutyrate. Intervention: 3-hydroxybutyrate</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Endotoxin, US standard reference E.coli</intervention_name>
    <arm_group_label>Placebo (isotonic saline)</arm_group_label>
    <arm_group_label>Acipimox + Placebo (isotonic saline)</arm_group_label>
    <arm_group_label>Acipimox + free fatty acids</arm_group_label>
    <arm_group_label>Acipimox + 3-hydroxybutyrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20 &lt; body mass index &lt; 30 kg/m2.

          -  written and orally informed consent before enrollment.

        Exclusion Criteria:

          -  participation in other studies using radioactive tracers or other exposure to
             radiation (X-rays, scintigraphy etc).

          -  allergy to soy products or eggs

          -  diabetes, any type

          -  epilepsy

          -  ongoing infection

          -  immune deficiency

          -  cardiovascular disease

          -  dysregulated hypertension

          -  primary muscles disease, congenital or acquired
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels MÃ¸ller, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Clinical Medicine, Aarhus University, Denmark. Department of Internal Medicin and Endocrinology, Aarhus university hospital, Aarhus, Denmark.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Research Laboratory, Department of Internal Medicine and Endocrinology</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2012</study_first_submitted>
  <study_first_submitted_qc>December 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2012</study_first_posted>
  <last_update_submitted>November 24, 2014</last_update_submitted>
  <last_update_submitted_qc>November 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>cytokine release</keyword>
  <keyword>fever</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acipimox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

